Case study: switching from ocrelizumab to cladribine

This patient wants to switch from an anti-CD20 therapy to oral cladribine in the hope that it is going to allow him to make an antibody response to the COVID-19 booster.

Case study

I am 38 years old and have been on ocrelizumab for just over 4 years. I have been double-jabbed with the Moderna mRNA COVID-19 vaccine and I have not seroconverted. I have been offered a booster dose, but I am not sure when to have it. My last ocrelizumab infusion was in July. Another worrying development is that I have recently developed hypo…

This post is for paying subscribers